Multicenter, Randomized and OpenⅡb Clinical Trials to Evaluate the Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients Harbouring T790M Mutation
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs Alflutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Allist Pharmaceuticals
- 04 Jul 2019 Planned End Date changed from 1 Jun 2019 to 1 Nov 2019.
- 04 Jul 2019 Status changed from not yet recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated